60 Degrees Pharmaceuticals (SXTP) Non-Current Assets (2022 - 2026)
60 Degrees Pharmaceuticals (SXTP) posted quarterly Non-Current Assets of $502877.0 for Q1 2026, up 53.49% year-over-year from $327636.0 in Q1 2025, and up 6.83% quarter-over-quarter from $470726.0 in Q4 2025.
60 Degrees Pharmaceuticals (SXTP) Non-Current Assets (2022 - 2026) Analysis & Trends
60 Degrees Pharmaceuticals (SXTP) has reported Non-Current Assets for 5 consecutive years, with $502877.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Assets rose 53.49% year-over-year to $502877.0; the TTM figure through Mar 2026 stood at $1.7 million (down 5.76% YoY), while the FY2025 annual figure was $470726.0, up 26.18% from the prior year.
- Non-Current Assets improved to $502877.0 in Q1 2026 per SXTP's latest filing, from $470726.0 in the prior quarter.
- Across five years, Non-Current Assets topped out at $1.7 million in Q2 2023 and bottomed at $198202.0 in Q4 2022.
- Historically, Non-Current Assets has averaged $510628.6 across 5 years, with a median of $470726.0 in 2025.
- Annual changes were most pronounced in 2023 — Non-Current Assets soared 173.05% — and 2024, when it tumbled 66.5%.
- 60 Degrees Pharmaceuticals' Non-Current Assets stood at $198202.0 in 2022, then jumped by 173.05% to $541183.0 in 2023, then tumbled by 31.06% to $373068.0 in 2024, then grew by 26.18% to $470726.0 in 2025, then rose by 6.83% to $502877.0 in 2026.
- Business Quant data shows SXTP's Non-Current Assets at $502877.0 in Q1 2026, $470726.0 in Q4 2025, and $380135.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 18.06 Bn |
| 10 | 60 Degrees Pharmaceuticals | 3.00 Mn | 1.98 Mn | 56,798.00 | 551,397.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 502,877.00 |
| Dec 31, 2025 | 470,726.00 |
| Sep 30, 2025 | 380,135.00 |
| Jun 30, 2025 | 337,583.00 |
| Mar 31, 2025 | 327,636.00 |
| Dec 31, 2024 | 373,068.00 |
| Sep 30, 2024 | 529,902.00 |
| Jun 30, 2024 | 564,106.00 |
| Mar 31, 2024 | 473,300.00 |
| Dec 31, 2023 | 541,183.00 |
| Sep 30, 2023 | 255,417.00 |
| Jun 30, 2023 | 1.68 Mn |
| Dec 31, 2022 | 198,202.00 |